Skip to main content
Tianjin Ringpu Bio-Technology Co.,Ltd. logo

Tianjin Ringpu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 300119 ISIN · CNE100000TV1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,284 across all filing types
Latest filing 2023-03-31 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300119

About Tianjin Ringpu Bio-Technology Co.,Ltd.

https://www.ringpu.com

Tianjin Ringpu Bio-Technology Co.,Ltd. is a high-tech enterprise specializing in the research, development, production, and sale of animal health products. The company offers a comprehensive portfolio that includes veterinary biological products, chemical drugs, feed additives, and pet health solutions. Its product range covers vaccines for poultry and livestock, as well as various pharmaceutical formulations such as injections, powders, and oral solutions. Ringpu Bio-Technology emphasizes innovation through its dedicated R&D centers, focusing on disease prevention and treatment to support the global animal husbandry industry. The company provides integrated health management services and high-quality veterinary medicines to ensure food safety and animal welfare.

Recent filings

Filing Released Lang Actions
2022年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2022 年度内部控制自我评价报告' which translates to '2022 Annual Internal Control Self-Evaluation Report'. It is issued by the company's board of directors and discusses the evaluation of the company's internal control effectiveness as of December 31, 2022. The content includes detailed descriptions of internal control scope, evaluation criteria, and conclusions about the absence of significant deficiencies in financial and non-financial internal controls. The document is comprehensive, contains substantive content about internal control evaluation, and is not merely an announcement or certification. It is not a full annual report (10-K) but a specialized report on internal control evaluation, which aligns with the definition of an Audit Report / Information (AR). Therefore, the document should be classified as an Audit Report / Information (AR). FY 2022
2023-03-31 Chinese
2022年度财务决算报告
Annual Report Classification · 95% confidence The document is titled '2022 年度财务决算报告' which translates to '2022 Annual Financial Settlement Report'. It contains detailed financial data for the full year 2022, including revenue, profit, assets, liabilities, cash flow, and explanations of major changes. The report mentions that the financial statements have been audited by an accounting firm with an unqualified opinion, indicating it is a full audited annual financial report. The length of the document (7188 characters) and the presence of comprehensive financial statements and analysis confirm it is the actual annual report rather than an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2022
2023-03-31 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the third meeting of the fifth board of directors of Tianjin Ruipu Biotechnology Co., Ltd. It includes approvals of various reports such as the 2022 annual board work report, financial statements, audit report, annual report, profit distribution plan, ESG report, internal control report, and other governance-related matters. It also mentions that these reports and documents have been or will be disclosed on the Shenzhen Stock Exchange and CNINFO websites. The document is not the reports themselves but a formal board meeting resolution announcement that these reports have been reviewed and approved and will be submitted to the 2022 annual general meeting for further approval. It also includes announcements of management changes and governance adjustments. Given the nature of the document as a board meeting resolution announcement covering multiple governance and management decisions, it fits best under the category of Board/Management Information (MANG). It is not a full annual report (10-K), audit report (AR), or other specific report but a board meeting resolution announcement.
2023-03-31 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed at the third meeting of the fifth Supervisory Board of Tianjin Ruipu Biotechnology Co., Ltd. It includes multiple agenda items such as approval of the 2022 Supervisory Board Work Report, 2022 Financial Final Accounts Report, 2022 Audited Financial Report, 2022 Annual Report and its summary, 2022 Profit Distribution Plan, and other related reports. Each item references the actual reports being disclosed on the Shenzhen Stock Exchange website and CNINFO, indicating that this document itself is not the full annual report or audit report but a meeting resolution announcement. The document also states that these resolutions will be submitted to the 2022 Annual General Meeting for approval. The document length is over 5,000 characters and contains substantive content about the meeting and resolutions, not just a brief notice. However, since it is a Supervisory Board meeting resolution announcement and not the actual reports, it fits best under Regulatory Filings (RNS) as it does not fit the other categories like Annual Report (10-K) or Audit Report (AR) which would contain the full reports themselves. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2023-03-31 Chinese
关于持股5%以上股东梁武增加一致行动人及持股在一致行动人之间内部转让计划转让数量过半暨转让计划完成的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the internal transfer of shares among shareholders holding more than 5% of the company's stock. It details the transfer plan, the parties involved, the number of shares transferred, and confirms that the overall shareholding percentage remains unchanged. There is no financial statement, earnings data, or management discussion. The document is a formal disclosure of shareholding changes and internal share transfers, which fits the category of Major Shareholding Notification (MRQ). The document length is 2761 characters, which is typical for such announcements. Therefore, the appropriate classification is MRQ.
2023-03-31 Chinese
关于对外投资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Tianjin Ruipu Biotechnology Co., Ltd. regarding an external investment transaction involving the acquisition of equity in Fujian Shengwei Biotechnology Co., Ltd. It details the transaction overview, parties involved, shareholding structure before and after the transaction, financial status of the target company, pricing basis, main contents of the equity transfer agreement, purpose and impact of the investment, and risk considerations. The document is a formal disclosure of a capital investment transaction and does not contain comprehensive financial statements or detailed financial performance analysis. It is not an annual or interim report, audit report, earnings release, or any other detailed financial report. It is an announcement about a capital investment transaction and changes in shareholding. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (5130 characters) and content support this classification with high confidence.
2023-03-21 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.